Lack of muscle toxicity with didanosine (ddI) clinical and experimental studies

Journal of the Neurological Sciences

Volumn 138, Issue 1-2, 1996, Pages 42-48

  Pedrol, Enric ^a   Masanés, Ferran ^a   Fernández Solá, Joaquim ^a   Cofan, Montserrat ^a   Casademont, Jordi ^a   Grau, Josep Maria ^a   Urbano Márquez, Alvaro ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

2 ,3 dideoxyinosine; Acquired immunodeficiency syndrome; Human immunodeficiency virus; Skeletal muscle culture; Toxic myopathy; Zidovudine

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOLOGY; HUMAN; MALE; MITOCHONDRION; MUSCLE; MUSCLE BIOPSY; MUSCLE TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ADULT; ANIMALS; ANTI-HIV AGENTS; BIOPSY; CELLS, CULTURED; DIDANOSINE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; RATS; RATS, WISTAR; RETROSPECTIVE STUDIES;

EID: 0029994738     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-510X(96)00009-3     Document Type: Article

References (52)

1. Abrams D.I., Goldman A.I., Launer C., et al. (1994) A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N. Engl. J. Med., 330: 657-662.
2. Ahluwalia G., Cooney D.A., Mitsuya H., et al. (1987) Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol., 36: 3797-3800.
3. Arnaudo E., Dalakas M., Shanske S., Moraes C.T., DiMauro S., Schon E.A. (1991) Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet, 337: 508-510.
4. Askanas V., Engel W.K. (1975) A new program for investigating adult human skeletal muscle grown aneurally in tissue culture. Neurology, 25: 58-67.
5. Banker B.Q. Engel A.G. (1986) Basic reactions of muscle. In: Engel AG, Banker BQ. (Ed.); Myology, Vol. 1., McGraw-Hill, New York, pp. 845-908.
6. Budka H., Wiley C.A., Kleihues P., et al. (1991) HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol., 1: 143-152.
7. Butler K.M., Husson R.N., Balis F.M., et al. (1991) Dideoxyinosine in children with symptomatichum immunodeficiency virus infection. N. Engl. J. Med., 324: 137-144.
8. Calabrese L.H., Estes M., Yen-Lieberman B., et al. (1989) Systemic vasculitis in association with human immunodeficiency virus infection. Arthritis Rheum., 32: 569-576.
9. Chalmers A.C., Greco C.M., Miller R.G. (1991) Prognosis in AZT myopathy. Neurology, 41: 1181-1184.
10. Chariot P., Ruet E., Authier F.J., Lévy Y., Gherardi R. (1994) Acute rhabdomyolysis in patients infected by human immunodeficiency virus. Neurology. 44: 1692-1696.
11. Collier A.C., Coombs R.W., Fischl M.A., et al. (1993) Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann. Intern. Med., 119: 786-793.
12. Connolly K.J., Allan J.D., Fitch H., et al. (1991) Phase I study of 2′-3′-dideoxyinosine administered orally twice daily of patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am. J. Med., 91: 471-478.
13. Cooley T.P., Kunches L.M., Saunders C.A., et al. (1990) Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N. Engl. J. Med., 322: 1340-1345.
14. Cooney D.A., Ahluwalia G., Mitsuya H., et al. (1987) Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol., 36: 1765-1768.
15. Dalakas M.C., Pezeshkpour G.H., Flaherty M. (1987) Progressive nemaline (rod) myopathy associated with HIV infection. N. Engl. J. Med., 317: 1602-1603.
16. Dalakas M.C., Wichman A., Sever J.L. (1989) AIDS and the nervous system. J. Am. Med. Assoc., 261: 2396-2399.
17. Dalakas M., Illa I. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy [letter]. N. Engl. J. Med., 323: 994.
18. Dalakas M.C., Illa I., Pezeshkpour G.H., Laukaits J.P., Cohen B., Griffin J.L. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med., 322: 1098-1105.
19. Darbyshire J.H., Aboulker J.P. (1992) Didanosine for zidovudine-in-tolerant patients with HIV disease. Lancet. 340: 1346-1347.
20. Doronzo R., Geremia L., Sacilotto G., Baron P.L., Scarpini E., Scarlato G. (1993) 2′,3′ Dideoxyinosine-induced acute rhabdomyolysis [abstract]. Clin. Neuropathol., 12: S45.
21. Faulds D., Brogden R.N. (1992) Didanosine. A review of its antiviral activity. Pharmacokinetic properties and therapeuthic potential in human immunodeficiency virus infection. Drugs, 44: 94-116.
22. Fischl M.A., Richman D.D., Grieco M.H., et al. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med., 317: 185-191.
23. Gabbai A.A., Schmidt B., Castelo A., Oliveira A.S.B., Lima J.G.S. (1990) Muscle biopsy in AIDS and ARC: analysis of 50 patients. Muscle Nerve, 13: 541-544.
24. Gertner E., Thurn J.R., Williams D.N., et al. (1989) Zidovudine-associated myopathy. Am. J. Med., 86: 814-818.
25. Gherardi R., Lebargy F., Gaulard P., Mhiri C., Bernaudin J.F., Gray F. (1989) Necrotizing vasculitis and HIV replication in peripheral nerves. N. Engl. J. Med., 321: 685-686.
26. Grau J.M., Masanés F., Pedrol E., Casademont J., Fernández-Solá J., Urbano-Márquez A. (1993) Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann. Neurol., 34: 206-211.
27. Hantaï D., Fournier J.G., Vazeux R., Collin H., Baudrimont M., Fardeau M. (1991) Skeletal muscle involvement in human immunodeficiency virus infection. Acta Neuropathol. (Berl.), 81: 496-502.
28. Helbert M., Fletcher T., Peddle B., Harris J.R.W., Pinching A.J. (1988) Zidovudine-associated myopathy. Lancet, 2: 689-670.
29. Jay Ch., Ropka M., Dalakas M. (1994) The drugs 2′,3′-dideoxyinosine (ddI) and 2′,3′-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy [letter]. J. Acquir. Immune Defic. Syndr., 7: 630-631.
30. Kahn J.O., Lagakos S.W., Richmann D.D., et al. (1992) A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N. Engl. J. Med., 327: 581-587.
31. Kaye B.R. (1989) Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). Ann. Intern. Med., 111: 158-167.
32. Kieburtz K.D., Seidlin M., Lambert J.S., Dolin R., Reichman R., Valentine F. (1992) Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex trated with dideodyinosine. J. Acquir. Immune Defic. Syndr., 5: 60-64.
33. Lambert J.S., Seidlin M., Reichman R.C., et al. (1990) 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N. Engl. J. Med., 322: 1333-1340.
34. Lamberth L., Dalakas M.C., Dagani F., Anderson J., Ferrari R. (1991) Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab. Invest., 65: 742-751.
35. Lewis W., Dalakas M.C. (1995) Mitochondrial toxicity of antiviral drugs. Nat. Med., 1: 417-422.
36. Lipsky J.J. (1993) Zalcitabine and didanosine. Lancet, 341: 30-32.
37. Merigan TC. (1991) Treatment of AIDS with combinations of antiretroviral agents. Am. J. Med., 90: 8S-17S.
38. Mhiri C., Baudrimont M., Bonne G., et al. (1991) Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol., 29: 606-614.
39. Molina J.M., Groopman J.E. (1989) Bone marrow toxicity of dideoxyinosine [letter]. N. Engl. J. Med., 321: 1478.
40. Moyle G.J., Nelson M.R., Hawkins D., Gazzard B.G. (1993) The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT). Q. J. Med., 86: 155-163.
41. Panegyres P.K., Tan N., Kakulas B.A., Armstrong J.A., Hollingsworth P. (1988) Necrotizing myopathy and zidovudine. Lancet, 1: 1050-1051.
42. Rozencweig M., McLaren C., Beltangady M., et al. (1990) Overview of phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev. Infect. Dis., 12 (suppl 5): s570-575.
43. Russell J.W., Klunk L.J. (1989) Comparative pharmacokinetics of new anti-HIV agents: 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Biochem. Pharmacol., 38: 1385-1388.
44. Sande M.A., Carpenter Ch.C.J., Cobbs G., Holmes K.K., Sanford J.P. (1993) Antiretroviral therapy for adult HIV-infected patients, recommendations from a state-of-the-art conference. J. Am. Med. Assoc., 270: 2583-2589.
45. Sandström E.G., Kaplan J.C. (1987) Antiviral therapy in AIDS. Drugs, 34: 372-390.
46. Shelton M.J., O'Donnell A.M., Morse G.D. (1992) Didanosine. Ann. Pharmacother., 26: 660-670.
47. Spruance S.L., Pavia A.T., Peterson D., et al. (1994) Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Ann. Intern. Med., 120: 360-368.
48. Till M., MacDonell K.B. (1990) Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? Ann. Intern. Med., 113: 492-494.
49. Urbano-Márquez A., Estruch R., Navarro-López F., Grau J.M., Mont Ll., Rubin E. (1989) The effects of alcoholism on skeletal and cardiac muscle. N. Engl. J. Med., 320: 409-415.
50. Valentine F.T., Seidlin M., Hochster H., Laverty M. (1990) Phase I study of 2′,3′-dideoxyinosine: experience with 19 patients at New York University Medical Center. Rev. Infect. Dis., 12 (suppl 5): s534-539.
51. Yarchoan R., Pluda J.M., Perno C.F., et al. (1990a) Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann. N.Y. Acad. Sci., 616: 328-343.
52. Yarchoan R., Pluda J.M., Thomas R.V., et al. (1990b) Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet. 336: 526-529.